Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506401 | 1.00 | USP30 (0.55) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL13606446 | 1.00 | USP30 (0.55) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL1055082 | 0.92 | USP30 (0.62) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL853539 | 0.92 | USP30 (0.62) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL13177349 | 0.92 | USP30 (0.62) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL14037432 | 0.92 | USP30 (0.62) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL853540 | 0.92 | USP30 (0.62) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL15312509 | 0.90 | USP30 (0.51) | USP30FUCA1L3MBTL1ATMALDH1A1 | |
| SCHEMBL4862883 | 0.88 | L3MBTL1 (0.57) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL21593409 | 0.88 | L3MBTL1 (0.57) | USP30L3MBTL1ATMALDH1A1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2005033076-A1 | METHOD FOR PREPARING 3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE COMPOUNDS | INDUSTRIAL RESEARCH LIMITED (NZ) | 2005-04-14 | — | — | WO | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| US-4786649-A | ANTISEPTICS | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-11-22 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| EP-0228035-A2 | Antimicrobial 1-thienyl-4-oxoquinoline-3-carboxylix acid compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | USP30 3425/4885FUCA1 4337/4885L3MBTL1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.